Lilly unveils multi‑dose Zepbound KwikPen; orforglipron reports strong data

Eli Lilly is widening its obesity playbook with a month-at-a-time Zepbound pen and a newly launched daily pill called Foundayo. (zepbound.lilly.com) (foundayo.lilly.com) Zepbound is tirzepatide, a once-weekly injection for adults with obesity, or overweight with a weight-related condition, and Lilly’s site now lists a single-patient-use KwikPen with four doses per pen. Lilly’s savings page says one “month” equals 28 days and can be dispensed as one KwikPen instead of four single-dose pens. (zepbound.lilly.com 1) (zepbound.lilly.com 2) (zepbound.lilly.com 3) The company is also using Zepbound beyond weight loss alone. Lilly says the drug is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, giving the brand a second labeled use as competition in obesity drugs shifts toward supply, delivery format, and insurance access. (zepbound.lilly.com 1) (zepbound.lilly.com 2) Foundayo is Lilly’s brand name for orforglipron, a glucagon-like peptide-1 receptor agonist, a class of drugs that helps regulate appetite and blood sugar. The United States Food and Drug Administration approved it on April 1, 2026, for adults with obesity, or overweight with at least one weight-related medical problem, alongside diet and exercise. (medical.lilly.com) (foundayo.lilly.com) Lilly’s launch message centers on convenience. The company says Foundayo is the only weight-loss glucagon-like peptide-1 pill that can be taken any time of day without food or water restrictions, and prescriptions began shipping through LillyDirect on April 6 before broader retail rollout. (prnewswire.com) (markets.ft.com) By April 9, Lilly said Foundayo was available through LillyDirect, telehealth providers, and retail pharmacies nationwide. The company said the list price path starts at $25 a month for commercially covered patients and $149 a month for self-pay patients. (markets.ft.com) (biospace.com) The head-to-head claim against oral semaglutide is not yet backed here by a published primary paper I could verify, but Lilly has completed a phase 3 diabetes study, ACHIEVE-3, comparing orforglipron with oral semaglutide in adults taking metformin. That trial enrolled 1,698 participants and ran from September 2023 to August 2025, which helps explain why comparison data are now surfacing in trade coverage. (trials.lilly.com) The practical split is straightforward: Zepbound is still Lilly’s injectable workhorse, and the KwikPen reduces the number of devices a patient handles in a month. Foundayo gives Lilly a pill option for patients who want to avoid injections, while keeping the company in the same fast-growing glucagon-like peptide-1 market. (zepbound.lilly.com) (foundayo.lilly.com) What happens next is less about whether Lilly has products in obesity and more about whether it can keep them easy to prescribe, easy to ship, and easy to pay for. In April 2026, it is trying to answer all three at once. (zepbound.lilly.com) (markets.ft.com)